261
Participants
Start Date
February 17, 2022
Primary Completion Date
March 11, 2024
Study Completion Date
April 2, 2024
rimegepant 75 mg ODT
One dose of rimegepant 75 mg ODT
Matching placebo
One dose of matching placebo
Northwell Health Department of Otolaryngology, New Hyde Park
Carolina ENT Clinic/CENTRI Inc., Orangeburg
Velocity Clinical Research, Anderson, Anderson
Velocity Clinical Research, New Smyrna Beach, Edgewater
The Medici Medical Research, LLC, Hollywood
Clinovation Research, Pompano Beach
Avantis Clinical Research, Miami
Kentuckiana Ear, Nose & Throat, Louisville
Allergy, Asthma & Sinus Center, S.C., Greenfield
ChicagoENT, Chicago
St Charles Clinical Research, Weldon Spring
University of Missouri Hospital & Clinics, ENT & Allergy Center of Missouri, Columbia
University of Missouri Healthcare - Investigational Pharmacy, Columbia
University of Missouri Hospital (Radiology), Columbia
Clinvest Research, LLC, Springfield
Best Clinical Trials, LLC (Administrative Only), New Orleans
George Stanley Walker, MD, New Orleans
Tekton Research, Inc., Edmond
Allergy, Asthma & Clinical Research Center, Oklahoma City
Vital Prospects Clinical Research Institute, P.C., Tulsa
Colorado ENT & Allergy, Colorado Springs
Treasure Valley Medical Research, Boise
Breathe Clear Institute, Torrance
National Research Institute, Panorama City
San Diego Clinical Research Center, La Mesa
Velocity Clinical San Diego, La Mesa
Sharp & Children's MRI Center, LLC (CT scan), San Diego
Sacramento Ear Nose and Throat Surgical and Medical Group, Inc., Roseville
Velocity Clinical Research, Medford, Medford
Velocity Clinical Research, Grants Pass, Grants Pass
Spokane Ear, Nose & Throat/ Columbia Surgical Specialists, Spokane
Principle Research Solutions, Spokane
Spokane Ear, Nose & Throat / Columbia Surgical Specialists, Spokane
Lead Sponsor
Pfizer
INDUSTRY